Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program

BACKGROUND: The development of abuse-deterrent opioid prescription medications is a priority at the national level. Pharmaceutical manufacturers have begun marketing new formulations of currently available opioids that meet higher abuse resistance standards. Little information is available regarding...

Descripción completa

Detalles Bibliográficos
Autores principales: L. Keast, Shellie, Owora, Arthur, Nesser, Nancy, Farmer, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398165/
https://www.ncbi.nlm.nih.gov/pubmed/27023688
http://dx.doi.org/10.18553/jmcp.2016.22.4.347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398165/
https://www.ncbi.nlm.nih.gov/pubmed/27023688
http://dx.doi.org/10.18553/jmcp.2016.22.4.347

Ejemplares similares